Corion Biotech’s Cell Therapy without Cells
Unique, sustainable & unlimited
source of therapeutic cells
Trophic mediators production
to exert the therapeutic abilities
Cells cultured ex-vivo
to exploit their therapeutic abilities and produce Corion biologics
No cells No DNA
in the final product, only therapeutic molecules
Highly scalable process
1 placenta = 1000 doses
Multiple therapeutic biologics
for women’s health
First in class
for Preeclampsia treatment
Preeclampsia affects 3-8% of all pregnancies worldwide, thus being the main cause of fetal-maternal mortality and morbidity worldwide. Preeclampsia is associated to Fetal Growth Restriction. Importantly, even though Preeclampsia resolves at delivery with placenta removal, it causes severe long term complications for both the mother and the newborn as cardiovascular and metabolic diseases, diabetes, neonatal neurological impairment, cerebral palsy and an increased risk of intellectual disability and autism spectrum disorders. It is evident that Preeclampsia has a massive social-economic burden, costing to the global health care system more than 3 billion USD/year with lifetime medical intervention. There are no effective therapeutic interventions for Preeclampsia except for a timed and often premature delivery, that represents itself an important risk factor for the newborn’s health.
Our technology is based on human PDMSCs purified from the human term placenta immediately after delivery, expanded and cultured in vitro in order to naturally obtain our preeclampsia therapeutic biological named CB-ChMF-11.
We recently successfully completed a Proof of Concept study to verify in-vivo on a recognized Preeclampsia animal model the efficacy and sustainability of our innovative therapeutic approach. CB-ChMF-11 reverted maternal hypertension and proteinuria as well as it significantly improved fetal outcome. Moreover, we reported CB-ChMF-11 beneficial effect also on the PE mice placenta after the in-vivo administration. In particular, CB-ChMF-11 significantly inhibited the placental production of detrimental molecules pivotal for preeclampsia onset.
A new drug for Preeclampsia represent both an important improvement for the health of millions of mothers and children and a substantial saving for sanitary systems in developed countries. The very positive outcome of the proof of concept study strongly supports CB-ChMF-11 as a key improvement for the therapy of preeclampsia, which is still an unsolved medical enigma. We are now entering in the Pre-clinical trial phase.
CB-ChMF-11 therapeutic approach for Preeclampsia is patented in EU and is extended in North America and Japan.
Epithelial cancers affecting ovarian and breast tissues represent the first cause of death among all gynecological cancers. Although most patients achieve complete clinical response following standard treatments, a very high percentage of them eventually relapse. Therefore, it is mandatory to develop new therapeutic strategies.
Corion Biotech approach for epithelial gynecological cancers is based on hPDMSCs purified from the human preeclamptic placenta obtained immediately after delivery, expanded and cultured in vitro in order to naturally obtain our therapeutic biological CB-ChMF-12.
CB-ChMF-12 demonstrated strong in-vitro anti-angiogenic action and inhibited the expression of pivotal oncogenes in the tumoral tissue, thus limiting cancer growth and metastatization. Therapeutic assumption: after the treatment with CB-ChMF-12, the constrained tumor can be easily and safely treated with traditional surgery.
CB-ChMF-12 is a cocktail of molecules naturally produced by human preeclamptic PDMSCs. We believe our approach offers a unique opportunity to treat epithelial cancers with a lower level of toxicity compared with current chemio-therapics.
CB-ChMF-12 therapeutic approach for Epithelial Tumors treatment is granted in Italy and pending in Europe, USA, Canada, China, Japan.